Sandu Pharma.

{
  "main_header": {
    "sid": 764862,
    "name": "Sandu Pharma.",
    "stock_name": "Sandu Pharma.",
    "full_name": "Sandu Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sandu-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "38.68",
    "chg": 0.93,
    "chgp": "2.46%",
    "dir": 1,
    "prev_price": "37.75",
    "mcapval": "36.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524703,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "India SENSEX",
    "isin": "INE751D01014",
    "curr_date": "May 19",
    "curr_time": "",
    "bse_nse_vol": "478 ",
    "exc_status": "Active",
    "traded_date": "May 19, 2026",
    "traded_date_str": "2026 05 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sandu Pharmaceuticals Declines 2.37% Despite Valuation Upgrade: 2 Key Factors Driving the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-declines-237-despite-valuation-upgrade-2-key-factors-driving-the-week-3994562",
        "imagepath": "",
        "date": "2026-05-16 15:08:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>11 May:</strong> Stock opens at Rs.39.02, down 0.76% as Sensex falls 1.40%</p>\n                    <p><strong>12 May:</strong> Continued decline to Rs.38.46 amid broader market weakness</p>\n                    <p><strong>13 May:</strong> Stock hits weekly low of Rs.37.48 following valuation upgrade announcement</p>\n                    <p><strong>14 May:</strong> MarketsMOJO upgrades rating to Sell on improved valuation metrics</p>\n                    <p><strong>15 May:</strong> Stock rebounds to Rs.38.39 despite Sensex retreat</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div c..."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Upgraded to Sell on Improved Valuation Metrics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-upgraded-to-sell-on-improved-valuation-metrics-3990572",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanduPharmaceut_mojoScore_3990572.png",
        "date": "2026-05-14 08:10:05",
        "description": "Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in its valuation metrics despite ongoing challenges in financial performance and technical indicators. This nuanced shift reflects a more attractive entry point for investors, even as the company continues to face headwinds in growth and profitability."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-3990336",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanduPharmaceut_valuationdot_3990336.png",
        "date": "2026-05-14 08:00:43",
        "description": "Sandu Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to a very attractive rating despite recent share price declines and a challenging market backdrop. This article analyses the company’s updated price-to-earnings (P/E) and price-to-book value (P/BV) ratios in comparison to historical levels and peer benchmarks, providing investors with a comprehensive view of its current price attractiveness."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3987314",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanduPharmaceut_mojoScore_3987314.png",
        "date": "2026-05-12 10:10:46",
        "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "When is the next results date for Sandu Pharmaceuticals Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-sandu-pharmaceuticals-ltd-3967217",
        "imagepath": "",
        "date": "2026-04-28 23:16:14",
        "description": "The next results date for Sandu Pharmaceuticals Ltd is scheduled for 05 May 2026...."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-signal-price-attractiveness-concerns-3965424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_valuationdot_3965424.png",
        "date": "2026-04-28 08:01:26",
        "description": "Sandu Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from fair to expensive territory, raising questions about its price attractiveness relative to historical levels and peer benchmarks. Despite recent gains in share price, the company’s micro-cap status and deteriorating mojo grade to a strong sell underscore investor caution amid stretched multiples."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3958955",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_mojoScore_3958955.png",
        "date": "2026-04-23 10:10:41",
        "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Sep 2024. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amid Mixed Market Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-to-fair-amid-mixed-market-returns-3943855",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_valuationdot_3943855.png",
        "date": "2026-04-13 08:00:51",
        "description": "Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 0.63%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market sentiment, raising questions about its price attractiveness relative to historical and peer benchmarks."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3941430",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_mojoScore_3941430.png",
        "date": "2026-04-10 10:10:44",
        "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 100,
    "sid": "764862",
    "stock_news_url": "https://www.marketsmojo.com/news/sandu-pharmaceuticals-764862"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "07-May-2026",
      "details": "Newspaper Publication for Audited Financials for the Q and Year ended 31.03.2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30-Update Demand Order From Office Of Assistant Commissioner Jurisdiction Sector 3 (Mobile Squad-1) Shamli State/UT Uttar Pradesh For Detention Of Conveyance & Goods Due To Discrepancy In Quantity As Per Invoice & Quantity As",
      "datetime": "07-May-2026",
      "details": "Demand order from office of assistant commissioner due to discrepancy in quantity as per invoice and quantity as per physical verification of Goods",
      "source": "BSE"
    },
    {
      "caption": "Statement Of Deviation And Variation Of Funds For Q Ended 31.03.2026",
      "datetime": "05-May-2026",
      "details": "Statement of Deviation and Variation of Funds for q ended 31.03.2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sandu Pharmaceuticals Ltd has declared <strong>8%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sandu Pharmaceuticals Declines 2.37% Despite Valuation Upgrade: 2 Key Factors Driving the Week

2026-05-16 15:08:59

Key Events This Week

11 May: Stock opens at Rs.39.02, down 0.76% as Sensex falls 1.40%

12 May: Continued decline to Rs.38.46 amid broader market weakness

13 May: Stock hits weekly low of Rs.37.48 following valuation upgrade announcement

14 May: MarketsMOJO upgrades rating to Sell on improved valuation metrics

15 May: Stock rebounds to Rs.38.39 despite Sensex retreat

Week Open

Read full news article

Sandu Pharmaceuticals Ltd Upgraded to Sell on Improved Valuation Metrics

2026-05-14 08:10:05

Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in its valuation metrics despite ongoing challenges in financial performance and technical indicators. This nuanced shift reflects a more attractive entry point for investors, even as the company continues to face headwinds in growth and profitability.

Read full news article

Sandu Pharmaceuticals Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-05-14 08:00:43

Sandu Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to a very attractive rating despite recent share price declines and a challenging market backdrop. This article analyses the company’s updated price-to-earnings (P/E) and price-to-book value (P/BV) ratios in comparison to historical levels and peer benchmarks, providing investors with a comprehensive view of its current price attractiveness.

Read full news article

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2026-05-12 10:10:46

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

When is the next results date for Sandu Pharmaceuticals Ltd?

2026-04-28 23:16:14

The next results date for Sandu Pharmaceuticals Ltd is scheduled for 05 May 2026....

Read full news article

Sandu Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Concerns

2026-04-28 08:01:26

Sandu Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from fair to expensive territory, raising questions about its price attractiveness relative to historical levels and peer benchmarks. Despite recent gains in share price, the company’s micro-cap status and deteriorating mojo grade to a strong sell underscore investor caution amid stretched multiples.

Read full news article

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2026-04-23 10:10:41

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Sep 2024. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amid Mixed Market Returns

2026-04-13 08:00:51

Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 0.63%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market sentiment, raising questions about its price attractiveness relative to historical and peer benchmarks.

Read full news article

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2026-04-10 10:10:44

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News